[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"familial-adenomatous-polyposis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:familial-adenomatous-polyposis":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,100,174,203,234,260,282,313,338,355,385,411,442,464,488],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":77,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":99},"100210159","integrated-cancer-repository-for-cancer-research-100210159",false,"NCT02012699","Integrated Cancer Repository for Cancer Research","iCaRe2","Inclusion Criteria\n\n* Diagnosis\u002Fhistory of cancer\n* Risk for developing cancer or suspicious clinical findings\n* No history of cancer (normal control registry)\n* Able to provide informed consent\n* 19 years of age or older\n* English or Spanish speaking individuals\n\nExclusion Criteria\n\n* Unable to provide informed consent because of cognitive impairment\n* Non-English or non-Spanish speaking individuals",true,"ALL","19 Years","110 Years",{"count":21,"type":22},999999,"ESTIMATED","80 Years","OBSERVATIONAL","The iCaRe2 is a multi-institutional resource created and maintained by the Fred \\& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76],"Pancreatic Cancer","Thyroid Cancer","Lung Cancer","Esophageal Cancer","Thymus Cancer","Colon Cancer","Rectal Cancer","Gastrointestinal Stromal Tumors","Anal Cancer","Bile Duct Cancer","Duodenal Cancer","Gallbladder Cancer","Gastric Cancer","Liver Cancer","Small Intestine Cancer","Peritoneal Surface Malignancies","Familial Adenomatous Polyposis","Lynch Syndrome","Bladder Cancer","Kidney Cancer","Penile Cancer","Prostate Cancer","Testicular Cancer","Ureter Cancer","Urethral Cancer","Hypopharyngeal Cancer","Laryngeal Cancer","Lip Cancer","Oral Cavity Cancer","Nasopharyngeal Cancer","Oropharyngeal Cancer","Paranasal Sinus Cancer","Nasal Cavity Cancer","Salivary Gland Cancer","Skin Cancer","Central Nervous System Tumor","Central Nervous System Cancer","Mesothelioma","Breast Cancer","Leukemia","Melanoma","Sarcoma","Unknown Primary Tumor","Multiple Myeloma","Ovarian Cancer","Endometrial Cancer","Vaginal Cancer","Neuroendocrine Tumors","Plasma Cell Dyscrasia","Healthy Control",[27,28,78,79,80,81,82,83,84,85,65,86,75,76],"Esophageal cancer","Thymus cancer","Pancreatic tumor","Esophageal tumor","Thymus tumor","Thyroid Tumor","Thyroid Nodule","Lung Tumor","Neuroendocrine tumor","RECRUITING","2026-06-25",{"date":90,"type":91},"2026-06-29","ACTUAL",{"date":93,"type":91},"2013-11-01",{"date":95,"type":22},"2099-12",{"name":97,"class":98},"University of Nebraska","OTHER",42,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":109,"conditions":110,"keywords":154,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":173},"100289631","familial-investigations-of-childhood-cancer-predisposition-100289631","NCT03050268","Familial Investigations of Childhood Cancer Predisposition","SJFAMILY","NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for this study as shown below, you may enroll regardless of the results of your clinical genetic testing.\n\nDEFINITION OF FAMILIAR CANCER FOR THIS PROTOCOL:\n\nIn this protocol, the definition of \"Familial Cancer\" is met if any of the following is present:\n\n* An individual with a history of cancer diagnosed under 26 years of age who has at least one first, second or third degree relative with a history of cancer diagnosed under 51 years of age; OR\n* An individual who has been diagnosed with more than one cancer, at least one of which was diagnosed under 26 years of age; OR\n* An individual with a clinical or molecular diagnosis of a known cancer predisposition syndrome; OR\n* An individual with a congenital cancer diagnosed before 6 months of age; OR\n* An individual with a rare pediatric cancer or tumor diagnosed before 26 years of age\n\nº Excluding human papilloma virus-associated cervical cancer and non-melanoma skin cancer occurring in adults.\n\nINCLUSION CRITERIA:\n\n* An individual who meets this protocol's definition of \"Familial Cancer,\" as above.\n* Biologic relatives of an individual meeting this protocol's definition of \"Familial Cancer,\" who are either affected or unaffected by cancer.\n\nEXCLUSION CRITERIA:\n\n* An inability or unwillingness of the research participant or his\u002Fher legally authorized representative (LAR) to provide written informed consent.\n* The participant has received allogeneic bone marrow transplantation and has NO pre-transplant germline (cancer-unaffected) DNA available AND is unwilling to provide a skin sample.",{"count":108,"type":22},1500,"NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for this study as shown in the Eligibility Section, you may enroll regardless of the results of your clinical genetic testing.\n\nWhile it is well recognized that hereditary factors contribute to the development of a subset of human cancers, the cause for many cancers remains unknown. The application of next generation sequencing (NGS) technologies has expanded knowledge in the field of hereditary cancer predisposition. Currently, more than 100 cancer predisposing genes have been identified, and it is now estimated that approximately 10% of all cancer patients have an underlying genetic predisposition.\n\nThe purpose of this protocol is to identify novel cancer predisposing genes and\u002For genetic variants. For this study, the investigators will establish a Data Registry linked to a Repository of biological samples. Health information, blood samples and occasionally leftover tumor samples will be collected from individuals with familial cancer. The investigators will use NGS approaches to find changes in genes that may be important in the development of familial cancer. The information gained from this study may provide new and better ways to diagnose and care for people with hereditary cancer.\n\nPRIMARY OBJECTIVE:\n\n* Establish a registry of families with clustering of cancer in which clinical data are linked to a repository of cryopreserved blood cells, germline DNA, and tumor tissues from the proband and other family members.\n\nSECONDARY OBJECTIVE:\n\n* Identify novel cancer predisposing genes and\u002For genetic variants in families with clustering of cancer for which the underlying genetic basis is unknown.",[111,112,113,114,115,116,117,118,119,120,121,122,123,43,124,125,126,127,128,129,130,131,132,133,44,134,135,136,137,138,139,140,141,142,143,144,27,145,146,147,148,149,150,151,152,153],"Acute Leukemia","Adenomatous Polyposis","Adrenocortical Carcinoma","AML","BAP1 Tumor Predisposition Syndrome","Carney Complex","Choroid Plexus Carcinoma","Constitutional Mismatch Repair Deficiency Syndrome","Diamond-Blackfan Anemia","DICER1 Syndrome","Dyskeratosis Congenita","Emberger Syndrome","Familial Acute Myeloid Leukemia","Fanconi Anemia","Familial Cancer","Familial Wilms Tumor","Familial Neuroblastoma","GIST","Hereditary Breast and Ovarian Cancer","Hereditary Paraganglioma-Pheochromocytoma Syndrome","Hodgkin Lymphoma","Juvenile Polyposis","Li-Fraumeni Syndrome","MDS","Melanoma Syndrome","Multiple Endocrine Neoplasia Type 1","Multiple Endocrine Neoplasia Type 2","Neuroblastoma","Neurofibromatosis Type 1","Neurofibromatosis Type II","Nevoid Basal Cell Carcinoma Syndrome","Non Hodgkin Lymphoma","Noonan Syndrome and Other Rasopathy","Overgrowth Syndromes","Peutz-Jeghers Syndrome","Pheochromocytoma\u002FParaganglioma","PTEN Hamartoma Tumor Syndrome","Retinoblastoma","Rhabdoid Tumor Predisposition Syndrome","Rhabdomyosarcoma","Rothmund-Thomson Syndrome","Tuberous Sclerosis","Von Hippel-Lindau Disease",[155,156,157,158,159,160,161,162,163],"Familial cancer","Genetic predisposition","Heritable disease","Cancer risk","Genome analysis","Genetic modifiers","Next generation sequencing (NGS)","Genetic counseling","DNA","2026-06-15",{"date":166,"type":91},"2026-06-17",{"date":168,"type":91},"2017-04-06",{"date":170,"type":22},"2037-03-31",{"name":172,"class":98},"St. Jude Children's Research Hospital",1,{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":17,"minAge":181,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":184,"phases":185,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":202},"100487723","phase-1-testing-for-safety-and-colorectal-cancer-preventive-effects-of-onc201-100487723","NCT05630794","Testing for Safety and Colorectal Cancer Preventive Effects of ONC201","Phase I Trial of ONC201 for Chemoprevention of Colorectal Cancer","Inclusion Criteria:\n\n* Be identified as high risk for recurrent colorectal adenomas, as defined by:\n\n  * A diagnosis of FAP AND\u002FOR\n  * Findings of either \\> 5 small (less than 1 cm) adenomas OR \\>= 3 with at least one \\>= 10 mm on most recent colonoscopy performed in the past 5 years\n* Be \\>= 18 years of age on day of signing informed consent\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 1 (Karnofsky \\>= 70%)\n* Leukocytes \\>= 3,000\u002Fmicroliter\n* Absolute neutrophil count \\>= 1,000\u002Fmicroliter\n* Platelets \\>= 100,000\u002Fmicroliter\n* Total bilirubin within normal institutional limits\n* Aspartate aminotransferase (AST) (serum (glutamic-oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT) (serum glutamic pyruvic transaminase (\\[SGPT\\]) =\\\u003C 1.5 x institutional upper limit of normal\n* Creatinine =\\\u003C 1.5 x institutional upper limit of normal\n* Participant is due to undergo a standard of care lower gastrointestinal (GI) colonoscopy for detection and removal of colorectal polyps. On this colonoscopy, participant is required to have:\n\n  * Two (2) adenomatous polyps of at least five (5) mm in size\n  * At least one (1) polyp within reach of a flexible sigmoidoscope (which will be retained in the colon or rectum and marked)\n  * In addition to polypectomy, six (6) biopsies of normal colonic mucosa \\>= 1 cm from a collected polyp will also be collected\n* Willing to undergo a second, research intent endoscopic procedure (either sigmoidoscopy or colonoscopy), approximately 12 weeks after initiating ONC201 treatment\n* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures\n* Life expectancy of at least 5-years\n* ONC201 is an imipridone agent with the potential for teratogenic or abortifacient effects. For this reason and because imipridones potential teratogenic effects are unknown, men and women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for four weeks after study treatment is completed. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should STOP the study medication and inform her study physician immediately\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Prior history of hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch syndrome\n* Participants may not be currently receiving any other investigational agents or have received any investigational agents within the past four weeks\n* Prior history of invasive colorectal cancer\n* Prior invasive active neoplasm that is progressing or requires active treatment within 3 years from registration. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. Participants with a history of prior invasive neoplasm diagnosed and treated greater than 3 years form registration may be considered with consultation of the primary investigator\n* Prior history of exposure to cytotoxic chemotherapy or ONC201\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to ONC201\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Pregnant and women who are nursing are excluded from this study because ONC201 is an imipridone agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events (AEs) in nursing infants secondary to treatment of the mother with ONC201, breastfeeding should be discontinued if the mother is treated with ONC201\n* Concomitant use of strong\u002Fmoderate CYP3A4\u002F5 inducers\u002Finhibitors. These agents must be discontinued at least 72-hours prior to beginning ONC201\n* Any of the following cardiac criteria:\n\n  * Prolongation of corrected QT (QTc) interval (QTc interval \\> 480 milliseconds, preferably using Frederica's QT correction formula), confirmed on electrocardiogram (ECG) tracings performed during screening\n  * A history of Torsades de pointes, heart failure, or family history of prolonged QT Syndrome\n* Concomitant use of drugs that are known to prolong QT and have a known risk of torsade de pointes (TdP) unless they are willing to stop these medications and possibly change to an alternative non-excluded medication to treat the same condition at least 72 hours prior to beginning ONC201","18 Years",{"count":183,"type":22},36,"INTERVENTIONAL",[186],"PHASE1","The purpose of this phase I trial is to test the safety and cancer preventive effects of different doses of ONC201 in people with familial adenomatous polyposis (FAP) or a history of multiple polyps. People with familial adenomatous polyposis (FAP) or a history of multiple polyps are at higher than average risk of developing colorectal cancer. ONC201, now known as dordaviprone, is a drug that may stop cancer cells from growing. This drug has been shown in previous studies to cause cancer cell death but not harm normal cells. If successful, this study may help us develop a new option for colorectal cancer prevention.",[189,190,43,191],"Colorectal Adenomatous Polyp","Colorectal Carcinoma","Multiple Adenomatous Polyps","2026-06-11",{"date":194,"type":91},"2026-06-12",{"date":196,"type":91},"2025-10-06",{"date":198,"type":22},"2028-03-01",{"name":200,"class":201},"National Cancer Institute (NCI)","NIH",5,{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":17,"minAge":181,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":184,"phases":213,"briefSummary":215,"conditions":216,"keywords":217,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":233},"100481726","phase-1-evaluate-rec-4881-in-participants-with-familial-adenomatous-polyposis-fap-100481726","NCT05552755","Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)","A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokintetics, and Pharmacodynamics of REC-4881 in Patients With Familial Adenomatous Polyposis (FAP)","TUPELO","Inclusion Criteria:\n\n1. Male or female and ≥ 18 years of age\n2. Have provided written informed consent to participate in the study\n3. Diagnosis of phenotypic classical FAP with disease involvement of the duodenum or the residual colon\u002Frectum\u002Fpouch as the primary disease site.\n4. Genetic diagnosis of FAP with APC gene mutation (Part 2 only).\n5. Has undergone colectomy or subtotal colectomy\n6. Spigelman Classification Stage II or higher.\n7. Investigator\u002FParticipant agrees to leave polyps ≤10 mm unresected during endoscopies performed at Screening and while on study\n8. Have no significant cardiovascular abnormalities at Screening:\n\n   1. Left ventricular ejection fraction \\>50% as determined on screening echocardiogram (ECHO)\u002F multi-gated acquisition (MUGA)\n   2. A QT interval corrected for heart rate using the Fridericia formula (QTcF) \\\u003C 450 msec in men and \\\u003C470 milliseconds (msec) in women.\n9. Have no significant hematopoietic abnormalities at Screening:\n\n   1. White blood cell count (WBC) ≥ 3,000\u002Fcubic millimeters (mm\\^3) (non-black populations); 2,700\u002Fmm\\^3 (black populations)\n   2. Platelet count ≥ 120,000\u002Fmm\\^3\n   3. Hemoglobin ≥ 10.0 grams (g)\u002Fdeciiter (dL)\n   4. No history of clinical coagulopathy.\n10. Have no significant hepatic abnormalities at Screening:\n\n    1. Total bilirubin ≤ 1.5 \\* upper limit of normal (ULN) (individuals with Gilbert syndrome may be enrolled)\n    2. Aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP) ≤ 2.0 \\* ULN.\n11. Have no significant renal abnormalities at Screening: serum creatinine ≤ 1.5 times \\* ULN.\n12. Female participants who are women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test within 24 hours before the first dose of study drug. If the urine test is positive or cannot be confirmed negative, a serum pregnancy test will be required and must be negative for the participant to be eligible.\n13. All participants must be willing to follow the contraceptive guidance in the protocol and must not be lactating or planning to attempt to become pregnant during the study or for a further period of 4 months after the last dose of study drug or impregnate someone during this study or for a further period of 14 weeks after the last dose of study drug.\n14. Absence of gross blood in stool at Screening; red blood on toilet paper only is acceptable.\n15. Participant must be willing to discontinue use of non-steroidal anti-inflammatory agents (NSAIDs) 6 weeks prior to Study Day 1 and remain off NSAIDs throughout the treatment period of the study (use of aspirin ≤ 700 milligrams \\[mg\\] week is allowed.)\n\nExclusion Criteria:\n\n1. Has any clinically significant laboratory abnormality, medical or psychiatric illness which, in the opinion of the Investigator, could interfere with the conduct or interpretation of the study or put the participant at risk.\n2. Has had prior pelvic irradiation.\n3. Has gastrointestinal disease or recent gastrointestinal procedure that could interfere with oral absorption of REC-4881, including difficulty swallowing capsules.\n4. Has received treatment with other investigational agents within the 4 weeks prior to Study Day 1 or a period during which the investigational agent has not been cleared from the body (that is, at least a period of 5 half-lives, if known), whichever is longer.\n5. Treatment with other FAP-directed drug therapy (such as off-label use of Balsalazide) within 8 weeks of screening endoscopy (Part 2 only) or had a Whipple procedure.\n6. Is currently under treatment for desmoid tumors.\n7. Use of omega-3 fatty acids or oral corticosteroids prior to Study Day 1\n8. Use of strong cytochrome P3A (CYP3A) inhibitors or inducers prior to Study Day 1\n9. History of an ongoing or newly diagnosed eye abnormality, including:\n\n   1. Retinal pathologies such as diabetic retinopathy, veno-occlusion, or macular edema\n   2. Corneal pathologies such as herpes keratitis, corneal dystrophy, corneal erosions, corneal degeneration, active or recurrent keratitis, or uveitis (intermittent, posterior, and\u002For panuveitis)\n   3. Other clinically significant ophthalmologic abnormalities (for example, retinal detachment) or has findings at Screening. \\[Participants with corrected myopia may be enrolled.\\]\n10. Has cancer at screening endoscopy in gastrointestinal (GI) tract (including stomach, duodenum, and colon\u002Frectum\u002Fpouch) (Part 2 only).\n11. Has a large polyp (\\>1 centimeter \\[cm\\]) not amenable to complete removal\n12. Has active pancreatitis secondary to pancreatic duct obstruction\n13. Has active gall bladder disease\n14. Is pregnant, lactating or is planning to attempt to become pregnant during this study or within 4 months after the last dose of study drug (women) or is planning to attempt to impregnate someone or donate sperm during the study or within 14 weeks after the last dose of study drug (men).\n15. Has had major surgery prior to Study Day 1\n16. Has an active infection requiring systemic therapy.\n17. Has known hypersensitivity to the study drug or its excipients.\n18. Has a history of alcohol or substance abuse within 1 year prior to screening for study participation, or is currently using alcohol, drugs of abuse, or any prescribed or over-the-counter medication in a manner which, in the opinion of the Investigator, indicates abuse.\n19. Received treatment with another mitogen-activated protein kinase (MEK) inhibitor 8 weeks prior to Screening and throughout the treatment period of the study.\n20. Any of the following known active infections:\n\n    1. Human immunodeficiency virus (HIV) not optimally controlled or treated. Participants with HIV who are on sustained stable antiretrovirals (for \\>4 weeks) and have cluster of differentiation (CD)4+ counts ≥ 350 cells\u002Fmicroliter (μL) may be enrolled. No HIV testing is required unless clinically indicated or mandated by local health authority.\n    2. Chronic hepatitis B virus (HBV) infection with surface antigen positive: participants with a prior history of treated HBV infection who are hepatitis B surface antigen-negative may be enrolled. No testing is required for hepatitis B unless clinically indicated or mandated by local health authority.\n    3. Chronic hepatitis C virus (HCV) infection: untreated or on active treatment. Participants with a prior history of treated HCV infection who are HCV RNA-undetectable may be enrolled. No testing is required for hepatitis C unless clinically indicated or mandated by local health authority.\n21. Has a severe or uncontrolled medical condition (for example, dermatologic disease, etc.) that, in the opinion of the Investigator, would pose a significant clinical risk for the participant.\n22. Use of strong Breast Cancer Resistance Protein (BCRP) or Multidrug Resistance-Associated Protein 2 (MRP2) inhibitors within 14 days of Study Day 1 and throughout the treatment period of the study.\n23. Clinically significant cardiovascular disease ≤ 6 months before first dose\n\n    1. Myocardial infarction or unstable angina\n    2. Clinically significant cardiac arrhythmias\n    3. Uncontrolled hypertension: systolic blood pressure (SBP) \\> 180 millimeters of mercury (mmHg), diastolic blood pressure (DBP) \\> 100 mmHg\n    4. Pulmonary embolism, symptomatic cerebrovascular events or any other serious cardiac condition (for example, pericardial effusion or restrictive cardiomyopathy)\n    5. QTcF prolongation \\>450 msec in males and \\>470 msec in females at screening or history of long QTc syndrome\n    6. Congestive heart failure (New York Heart Association class III-IV)\n    7. Myocarditis \u002F clinically significant pericarditis.\n    8. Atrial enlargement.",{"count":212,"type":22},67,[186,214],"PHASE2","This is a multicenter, two-part trial in participants with FAP.",[43],[218,219,220,221,222],"FAP","familial adenomatous polyposis","APC mutation","adenomatous polyposis coli","desmoid disease","2026-06-03",{"date":225,"type":91},"2026-06-05",{"date":227,"type":91},"2023-07-10",{"date":229,"type":22},"2027-09",{"name":231,"class":232},"Recursion Pharmaceuticals Inc.","INDUSTRY",17,{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":17,"minAge":181,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":243,"conditions":244,"keywords":245,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":259},"100563328","microbial-and-environmental-factors-associated-with-polyps-development-in-familial-adenomatous-polyposis-microbenvironment-in-fap-100563328","NCT06614738","Microbial and Environmental Factors Associated With Polyps Development in Familial Adenomatous Polyposis (MicrobEnvironment in FAP)","Microbial and Environmental Factors Associated With Polyps Development in Familial Adenomatous Polyposis","Inclusion Criteria:\n\n* ≥18 years\n* Non-opposition obtained\n* Prophylactic colectomy for at least 2 years in the context of APC-related familial adenomatous polyposis with ileorectal or ileoanal anastomosis\n* Included in the national POLYPOSE database\n* Regular endoscopic follow-up with upper and lower GI endoscopy at Hôpital Edouard Herriot or Hôpital de la Croix-Rousse\n* Having performed at least 2 endoscopies as part of follow-up\n\nExclusion Criteria:\n\n* Antibiotic therapy within 2 months prior to stool sampling\n* Taking probiotics for less than 1 month\n* Person deprived of liberty by judicial or administrative decision",{"count":242,"type":22},100,"Familial adenomatous polyposis (FAP) is an autosomal dominant inherited disorder linked to a mutation in the APC gene, associated with the development of multiple colonic and duodenal adenomas, which in 100% of cases progress to colorectal cancer (CRC) if left untreated. Management of affected patients is usually based on prophylactic total colectomy with or without rectal preservation, followed by regular endoscopic surveillance of the duodenum and rectum or ileal reservoir. However, there is considerable inter- and intra-familial variability in the rate of adenoma appearance and development for identical mutations. This strongly suggests the additional role of environmental factors. Recently, the gut microbiota has been identified as a co-factor of carcinogenesis in patients with FAP, but no prospective evaluation of the association between the incidence and severity of adenomatous proliferations and a microbiological signature has been studied, particularly at duodenal level in operated patient.",[43],[246,247,248,249],"Familial adenomatous polyposis","microbiota","colorectal cancer","nutrition","2026-05-22",{"date":252,"type":91},"2026-05-27",{"date":254,"type":91},"2024-12-17",{"date":256,"type":22},"2029-05-17",{"name":258,"class":98},"Hospices Civils de Lyon",2,{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":17,"minAge":181,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":184,"phases":269,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":259},"100565371","trial-of-exercise-therapy-in-familial-adenomatous-polyp-fap-100565371","NCT06641310","Trial of Exercise Therapy in Familial Adenomatous Polyp (FAP)","Phase 1a\u002Fb Trial of Exercise Therapy in Familial Adenomatous Polyp (FAP)","Inclusion Criteria:\n\n* Individuals with FAP as defined by:\n\n  * Genetic diagnosis: APC germline mutation (with or without FAP family history), OR\n  * Clinical diagnosis: FAP phenotype with a history of more than 50 colorectal adenomas\n* Have an intact rectum defined as status post colectomy and ileocolonic anastomosis for polyposis or pre-colectomy\n* ≥ 5 rectal polyps \\> 2 mm in size on baseline lower endoscopy\n* Participants must have no evidence of invasive cancer for 6 months prior to screening and must be at least 6 months from any prior cancer-directed treatment (such as surgical resection, chemotherapy, immunotherapy, hormonal therapy or radiation)\n* No initiation of daily use of sulindac, celecoxib or other non-steroidal anti-inflammatory medications (NSAIDs) within 3 months of day 1 and no initiation \\> 25% of the time (\\> 8 days\u002Fmonth) for the duration of study participation\n* No initiation of semaglutide, liraglutide (glucagon-like peptide-1 receptor agonist \\[GLP-1 receptor agonist\\]), tirzepatide (glucose-dependent insulinotropic polypeptide \\[GIP\\]), orlistat (lipase inhibitor) or other weight loss medications, within 3 months of day 1 and during study participation\n* Adults ≥ 18 years of age\n* Human immunodeficiency virus (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial\n* For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\n* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* Participants on chronic suppressive antiviral therapy for herpes simplex virus (HSV) are eligible\n* Lower endoscopy, required for participation in the study, is contraindicated in pregnancy. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and until after the end of study endoscopy is completed. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform the study team immediately\n* Inactive defined as ≤ 60 minutes of moderate or strenuous exercise per week over the past month as assessed by the Godin Leisure Time Exercise Questionnaire\n* No self-reported contraindications to regular exercise as evaluated by the Physical Activity Readiness Questionnaire (PAR-Q+)\n* Sufficient space to house a treadmill in primary residence for the intervention period or access to an approved treadmill (as determined by study exercise physiologist) for the intervention period (e.g., participant may have access to a treadmill via an existing membership to a health club)\n* Ability for study team to deliver and install exercise equipment in primary residence\n\n  * Note: If participant will be using treadmill from another source approved by study exercise physiologist, this inclusion criteria is not applicable\n* Internet or Wi-Fi connection. For participants without internet or Wi-Fi, a pre-paid cellular iPad will be provided\n* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures\n* Physician approval\n* Ability to understand and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* History of total proctocolectomy\n* Histologically-confirmed high-grade dysplasia or cancer on biopsy at screening\n* History of pelvic radiation\n* Participants receiving any other investigational agents\n* Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* History of severe, progressive, or uncontrolled renal, genitourinary, hepatic, hematologic, endocrine, cardiac, vascular, pulmonary, rheumatologic, neurologic, psychiatric, or metabolic disturbances, or signs and symptoms thereof\n* Pregnant women are excluded since endoscopy is not recommended while pregnant",{"count":268,"type":22},32,[270],"NA","The purpose of this phase 1a\u002Fb trial is to find out what amount of exercise would be best to use for preventing recurrence of colorectal polyps. It involves following one of four different amounts of exercise regimens on a treadmill for 26 weeks. A treadmill will be placed in each study participant's home for the duration of the study. The exercise regimen will be personalized for each participant and monitored remotely by exercise personnel. The in-person study visits occur during the usual standard of care endoscopy exam and during a follow-up exam that is 26 weeks later. Small rectal tissue biopsies, about the size of a grain of rice, will be taken before and after 26 weeks of exercise. The study visits also involve questionnaires, a stool sample, and a blood sample. This study will inform the design of larger, future trials to investigate whether or not recurrence of polyps can be achieved with exercise.",[43],"2026-05-18",{"date":275,"type":91},"2026-05-19",{"date":277,"type":91},"2026-05-13",{"date":279,"type":22},"2028-05",{"name":281,"class":98},"University of Michigan Rogel Cancer Center",{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":17,"minAge":290,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":184,"phases":294,"briefSummary":295,"conditions":296,"keywords":297,"overallStatus":302,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":312},"100539792","phase-2-safety-study-for-the-use-of-rapamycin-in-children-with-familial-adenomatous-polyposis-100539792","NCT06308445","Safety Study for the Use of Rapamycin in Children With Familial Adenomatous Polyposis","Safety Study for the Use of Rapamycin in Children With Familial Adenomatous Polyposis.","RAPA-4-PAF","Inclusion Criteria:\n\n* Children aged 12 to 17 at time of inclusion.\n* Patients with colonoscopy for diagnosis or follow-up of FAP.\n* ≥ 5 polyps (\\> 2 mm) at initial colonoscopy (V1).\n* Free and informed consent, signed by both holders of parental authority\u002Flegal representative, with the accord of the minor patient.\n* Affiliated with a social security scheme.\n* Patients of childbearing potential must agree to the use of a method of contraception during the study.\n\nExclusion Criteria:\n\n* Inability to understand the nature and goals of the study and\u002For communication difficulties observed by the investigator.\n* Contraindication to performing a colonoscopy.\n* \\\u003C 5 polyps (\\>2 mm) registered during initial colonoscopy (V1).\n* Advanced disease with high-grade dysplasia adenoma or even adenocarcinoma in situ that should required colectomy\n* Signs of primary tuberculosis infection or respiratory infection\n* Any other medical or psychological condition deemed incompatible with the proper conduct of the study according to the investigator.\n* Contraindications to rapamycin use\n* Participation in other biomedical research\n* Deprivation of liberty of the legal guardians by judicial or administrative decision.\n* Pregnancy, breastfeeding","12 Years","17 Years",{"count":293,"type":22},25,[214],"The hypothesize of this research is that rapamycin is effective and well-tolerated in teenagers with familial adenomatous polyposis (FAP). Rapamycin could be effective in blocking the formation of adenomas and\u002For their evolution by decreasing their size and number. Researchers aim to assess the safety profile of rapamycin in FAP adolescents using a 2 low dose regimen.",[43],[298,299,300,301],"Safety use","rapamycin","prophylaxis","teenager","NOT_YET_RECRUITING","2026-05-04",{"date":305,"type":91},"2026-05-08",{"date":307,"type":22},"2026-09-01",{"date":309,"type":22},"2030-09",{"name":311,"class":98},"University Hospital, Toulouse",4,{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":17,"minAge":181,"maxAge":4,"enrollmentInfo":319,"targetDuration":321,"studyType":24,"phases":4,"briefSummary":322,"conditions":323,"keywords":324,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":259},"100414544","a-personalized-surveillance-and-intervention-protocol-for-duodenal-and-gastric-polyposis-in-patients-with-familial-adenomatous-polyposis-100414544","NCT04677998","A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis","Inclusion Criteria:\n\n* Diagnosis of FAP, at least one of following: genetic diagnosis (proven APC germline mutation) and\u002For clinical diagnosis (\\>100 colorectal adenomas in combination with a positive family history of FAP)\n* Age 18 years or older\n\nExclusion Criteria:\n\n* Endoscopic removal of all polyps with an indication for removal not possible\u002Ffeasible\n* Gastric or duodenal cancer at baseline endoscopy\n* Need for surgery",{"count":320,"type":22},1000,"5 Years","The purpose of this study is to determine the efficacy and safety of a personalized surveillance and intervention protocol for duodenal and gastric polyposis in patients with familial adenomatous polyposis (FAP)",[43],[325,326,327,328],"Endoscopic surveillance","Endoscopic interventions","Personalized care","Gastrointestinal neoplasia","2026-02-20",{"date":331,"type":91},"2026-02-23",{"date":333,"type":91},"2020-11-24",{"date":335,"type":22},"2027-11",{"name":337,"class":98},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":17,"minAge":181,"maxAge":4,"enrollmentInfo":344,"targetDuration":321,"studyType":24,"phases":4,"briefSummary":345,"conditions":346,"keywords":347,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":349,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":259},"100414545","a-personalized-surveillance-and-intervention-protocol-for-patients-with-familial-adenomatous-polyposis-that-have-undergone-proctocolectomy-100414545","NCT04678011","A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy","Inclusion Criteria:\n\n* Diagnosis of FAP, at least one of following: genetic diagnosis (proven APC germline mutation) and\u002For clinical diagnosis (\\>100 colorectal adenomas in combination with a positive family history of FAP)\n* Have undergone prophylactic (procto)colectomy with IRA\u002FISA or IPAA\n* Age 18 years or older\n\nExclusion Criteria:\n\n* Not able to remove all polyps with an indication for removal during (multiple) clearing endoscopies\n* Cancer at baseline endoscopy\n* Need for surgery",{"count":320,"type":22},"The purpose of this study is to determine the efficacy and safety of a personalised surveillance and intervention protocol for patients with familial adenomatous polyposis (FAP) that have undergone (procto)colectomy.",[43],[325,326,348,328],"Personalised care",{"date":331,"type":91},{"date":351,"type":91},"2021-11-24",{"date":353,"type":22},"2026-11",{"name":337,"class":98},{"id":356,"slug":357,"hasResults":11,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":361,"eligibilityCriteria":362,"healthyVolunteers":11,"sex":17,"minAge":181,"maxAge":4,"enrollmentInfo":363,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":365,"conditions":366,"keywords":374,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":259},"100608251","duodenal-polyposis-classification-in-fap-100608251","NCT07199127","Duodenal Polyposis Classification in FAP","Novel Endoscopic Classification for Duodenal Polyposis in Individuals With Familial Adenomatous Polyposis","DRACO","Inclusion Criteria:\n\n* Confirmed germline diagnosis of FAP, as defined by genetic testing\n* Two or more upper gastrointestinal endoscopies\n* Complete documentation of all Spigelman classification variables at each endoscopic evaluation\n\nExclusion Criteria:\n\n* Histological grading of duodenal polyps incomplete\n* Follow-up data were unavailable\n* Duodenal surgery before study baseline endoscopy",{"count":364,"type":22},300,"Duodenal cancer is the leading cause of cancer-related mortality in patients with familial adenomatous polyposis (FAP), yet the current Spigelman staging system provides limited predictive accuracy for advanced neoplasia. The DRACO study (Duodenal Risk Assessment in adenomatous polyposis Coli -Oncogene) is a multicenter, STROBE- and CONSORT-compliant cohort study that analyzes upper endoscopies from genetically confirmed FAP patients across independent cohorts to develop, validate, and externally test two multivariable risk models.",[367,43,368,369,370,218,371,372,373],"Duodenum Cancer","Duodenal Polyposis","Ampulla of Vater Adenoma","FAP Gene Mutation","Duodenal Neoplasms","Duodenal Adenoma","Ampulla of Vater Cancer",[375,368],"Spigelman","2025-09-22",{"date":378,"type":91},"2025-09-30",{"date":380,"type":91},"2018-02-02",{"date":382,"type":22},"2030-01-15",{"name":384,"class":98},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",{"id":386,"slug":387,"hasResults":11,"nctId":388,"briefTitle":389,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":11,"sex":17,"minAge":181,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":184,"phases":394,"briefSummary":395,"conditions":396,"keywords":397,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":173},"100560552","investigation-of--hydroxybutyrate-supplementation-as-chemoprevention-in-familial-adenomatous-polyposis-100560552","NCT06578637","Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis","BHB-FAP","Part A\n\nInclusion Criteria:\n\n1. Have a diagnosis of FAP with genetic testing demonstrating a pathogenic or likely pathogenic germline variant in APC, must have a clinical FAP phenotype with at least one member of the family who has a pathogenic or likely pathogenic germline variant in APC, or must have a clinical diagnosis of FAP as agreed by two gastrointestinal cancer genetics experts\n2. Must have an extensive colonic resection with either a subtotal colectomy with ileorectal anastomosis (STC-IRA) or total proctocolectomy with ileal pouch anal anastomosis (TPC-IPAA)\n3. Can provide informed consent\n\nExclusion Criteria:\n\n1. Subject is pregnant, a prisoner, or is under 18 years of age\n2. Prior total proctocolectomy with end ileostomy\n3. History of inflammatory bowel disease\n4. History of diabetes mellitus and are currently on medical diabetes therapy\n5. History of chronic kidney disease with an eGFR \\< 60 mL\u002Fmin\u002F1.73m2\n6. Cancer diagnosis where the subject is receiving active therapy\n7. Use of either a ketogenic diet or intermittent fasting (defined as a fasting period of 16 hours or more per day that is not associated with a medical procedure) during the 4 weeks prior to enrollment\n\nPart B\n\nInclusion Criteria:\n\n1. Have a diagnosis of FAP with genetic testing demonstrating a pathogenic or likely pathogenic germline variant in APC, must have a clinical FAP phenotype with at least one member of the family who has a pathogenic or likely pathogenic germline variant in APC, or must have a clinical diagnosis of FAP as agreed by two gastrointestinal cancer genetics experts.\n2. Willing to undergo a colonoscopy or sigmoidoscopy, which may be part of the patient's routine standard care.\n3. Able to have a concurrent upper endoscopy performed with the colonoscopy\u002Fsigmoidoscopy. This upper endoscopy may be part of the patient's routine standard care.\n4. Have at least two colorectal polyps at enrollment (which can be present anywhere in the colon including the rectal cuff, or in the J-pouch \\[if applicable\\]).\n5. Can provide informed consent.\n\nExclusion Criteria:\n\n1. Subject is pregnant, a prisoner, or is under 18 years of age\n2. Patient is not able to undergo colonoscopy\u002Fsigmoidoscopy or upper endoscopy\n3. Prior total proctocolectomy with end ileostomy\n4. History of inflammatory bowel disease\n5. History of diabetes mellitus and are currently on medical diabetes therapy\n6. History of chronic kidney disease with an eGFR \\\u003C 60 mL\u002Fmin\u002F1.73m2\n7. Cancer diagnosis where the subject is receiving active therapy\n8. Use of either a ketogenic diet or intermittent fasting (defined as a fasting period of 16 hours or more per day that is not associated with a medical procedure) during the 4 weeks prior to enrollment\n9. Regular use of any FAP-related chemopreventive agent in the 6 weeks prior to enrollment including aspirin (\\> 81mg daily), NSAIDs, BHB supplementation, or any other medication deemed a chemopreventive agent by the study investigators\n10. Any colonic or small intestinal polyp observed endoscopically that is \\> 1 cm in size and is not removed (excluding ampullary adenomas)",{"count":393,"type":22},20,[270],"The aim of this study is to evaluate the potential of BHB supplementation as a novel strategy to impede the development and progression of intestinal adenomas in individuals with FAP, thus potentially reducing the need for frequent upper endoscopies and colonoscopies and preventing the need for risk-reducing surgical intervention.",[218,43],[218,246,398,399,400,401],"Chemoprevention","Polyps","BHB","Beta-hydroxybutyrate","2025-08-27",{"date":404,"type":91},"2025-09-04",{"date":406,"type":91},"2024-09-20",{"date":408,"type":22},"2027-10",{"name":410,"class":98},"Abramson Cancer Center at Penn Medicine",{"id":412,"slug":413,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":11,"sex":17,"minAge":181,"maxAge":419,"enrollmentInfo":420,"targetDuration":4,"studyType":184,"phases":422,"briefSummary":423,"conditions":424,"keywords":426,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":259},"100557460","ten-versus-fifteen-centimeter-pouch-in-ipaa-surgery-100557460","NCT06538402","Ten Versus Fifteen Centimeter Pouch in IPAA Surgery","Ileal Reservoir Length and Functional Outcome in Ileal Pouch-anal Anastomosis","TESTIMONY","Inclusion Criteria:\n\n* Undergoing ileal pouch-anal anastomosis (IPAA) for ulcerative colitis or familial adenomatous polyposis (FAP) (implying a normal sphincter function as judged by history and clinical examination)\n* Signed informed consent\n* Able to perform both a small (10 cm) and medium-size (15 cm) pouch with adequate reach and no tension as determined subjectively by the surgeon intraoperatively","60 Years",{"count":421,"type":22},120,[270],"The aim of this randomized controlled trial is to compare outcome after construction of an ileal (J-shaped) reservoir of 10 versus 15 centimeters in primary ileal pouch-anal anastomosis surgery.",[425,43],"Ulcerative Colitis",[427,428,219,429,430,431,432],"ileal pouch-anal anastomosis","ulcerative colitis","randomized controlled trial","pouch function","quality of life","complications","2025-07-04",{"date":435,"type":91},"2025-07-09",{"date":437,"type":91},"2025-07-03",{"date":439,"type":22},"2038-07-03",{"name":441,"class":98},"Odense University Hospital",{"id":443,"slug":444,"hasResults":11,"nctId":445,"briefTitle":446,"officialTitle":446,"acronym":447,"eligibilityCriteria":448,"healthyVolunteers":11,"sex":17,"minAge":181,"maxAge":449,"enrollmentInfo":450,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":451,"conditions":452,"keywords":453,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":173},"100321938","cold-snare-polypectomy-for-duodenal-adenomas-in-familial-adenomatous-polyposis-100321938","NCT03471403","Cold Snare Polypectomy for Duodenal Adenomas in Familial Adenomatous Polyposis","COPDA","Inclusion Criteria:\n\n* Patient's diagnosed with a confirmed diagnosis of FAP (genetic testing) and able to give informed consent to involvement in trial. For patients who do not speak English, an interpreter will be asked to translate the informed consent\n* Patients already commenced on endoscopic surveillance for FAP.\n\nExclusion Criteria:\n\n* Patient's with known strictures\u002Fstenosis\n* Pregnancy\n* Patients who did not consent to study\n* Bleeding diathesis","99 Years",{"count":242,"type":22},"The purpose of this study is to collect prospective observational data regarding patients with diagnosed Familial Adenomatous Polyposis (FAP) undergoing cold snare polypectomy for duodenal adenomas",[43],[454],"Cold snare polypectomy","2025-03-25",{"date":457,"type":91},"2025-03-27",{"date":459,"type":91},"2017-10-10",{"date":461,"type":22},"2028-10-10",{"name":463,"class":98},"Western Sydney Local Health District",{"id":465,"slug":466,"hasResults":11,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":11,"sex":17,"minAge":471,"maxAge":472,"enrollmentInfo":473,"targetDuration":4,"studyType":184,"phases":475,"briefSummary":477,"conditions":478,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":173},"100558008","phase-3-chemopreventive-effect-of-combination-of-celecoxib-and-metformin-in-patients-with-familial-adenomatous-polyposis-100558008","NCT06545526","Chemopreventive Effect of Combination of Celecoxib and Metformin in Patients With Familial Adenomatous Polyposis","The Chemopreventive Effect of Celecoxib Monotherapy Versus Combination of Celecoxib and Metformin in Patients With Familial Adenomatous Polyposis: a Pilot Randomized, Open-label, Comparative Study","Inclusion Criteria:\n\n\\- 1. Patients with familial adenomatous polyposis(FAP) who are 20 to 55 years of age.\n\n2\\. FAP patients who have colonic or duodenal polyp. 3. FAP patients who have five or more polyps 2mm or more in diameter in endoscopic examination.\n\nExclusion Criteria:\n\n* 1\\. FAP patients who had a history of colectomy within the previous 12 months or need to undergo colectomy within 8 months after randomization.\n\n  2\\. FAP patients with malignant disease, including colorectal cancer. 3. FAP patients who used NSAIDs (non-steroidal anti-inflammatory drugs) or aspirin three or more times a week within 3 months of randomization.\n\n  4\\. Pregnant or breast-feeding patients. 5. Patients with cardiovascular diseases, peptic ulcer diseases and diabetes. 6. Patients with abnormal results of serum laboratory tests (renal function and liver function test).","20 Years","55 Years",{"count":474,"type":22},28,[476],"PHASE3","Familial adenomatous polyposis (FAP) leads to adenomas and eventual adenocarcinomas in colon and less frequently, duodenum. Chemopreventive strategies have been studied in FAP patients to delay the development of adenomas and cancers. The non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase-2 inhibitor have shown the regression of colorectal and duodenal adenomas in FAP patients. However, these drugs showed gastrointestinal damage and cardiovascular risks, and new preventive strategies are needed. Metformin, an anti-diabetic drug, has recently been suggested to have a suppressive effect on tumorigenesis via inhibition of mTOR pathway, and have an inhibitory effect on polyp recurrence after removal of sporadic colorectal polyps. In addition, metformin has a number of potential mechnisms of carciovascular bebefit. We devised a randomized, open-label, comparative study to evaluate the effect of combination of celecoxib and metformin on polyps of colorectum and duodenum in FAP patients.",[43],"2024-08-05",{"date":481,"type":91},"2024-08-09",{"date":483,"type":22},"2024-08-13",{"date":485,"type":22},"2026-06-30",{"name":487,"class":98},"Yonsei University",{"id":489,"slug":490,"hasResults":11,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":4,"eligibilityCriteria":494,"healthyVolunteers":11,"sex":17,"minAge":181,"maxAge":495,"enrollmentInfo":496,"targetDuration":498,"studyType":24,"phases":4,"briefSummary":499,"conditions":500,"keywords":4,"overallStatus":302,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":173},"100403333","colorectal-adenoma-canceration-in-fap-100403333","NCT04531930","Colorectal Adenoma Canceration in FAP","Cohort Study on Colorectal Adenoma Canceration in Familial Adenomatous Polyposis","Inclusion Criteria:\n\n* The initial number of polyps is between 100-1000 visually;\n* Pathological diagnosis of multiple lesions confirmed colorectal adenoma;\n* Germline mutation detection is clearly a point mutation or large deletion of APC gene;\n* No cancer or distant metastasis.\n\nExclusion Criteria:\n\n* Age \\\u003C18, or \\>40 years old;\n* The initial number of polyps is \\\u003C100, or \\>1000;\n* The polyp has become cancerous or has suspected distant metastasis;\n* Patients with intestinal obstruction, intestinal perforation, intestinal bleeding and other patients who need emergency surgical resection;\n* Past history of colorectal surgery;\n* Suffering from malignant tumors in other parts and requiring treatment or using chemotherapy drugs or NSAIDs;\n* The patient has contraindications to colonoscopy;\n* Patients or family members cannot understand the conditions and goals of this study;\n* The patient plans to receive surgical treatment of preventive colorectal resection;\n* Other reasons considered by the study doctor to be inappropriate for inclusion in the study.","40 Years",{"count":497,"type":22},124,"10 Years","The current internationally accepted treatment method for familial adenomatous polyposis is prophylactic total colorectal resection combined with endoscopic follow-up. However, total colorectal resection will bring a sharp decline in the quality of life of patients. Therefore, how to improve treatment methods and improve the quality of life for such patients under the premise of medical quality is the current medical focus. This study intends to establish three parallel observation cohorts, namely the surgical treatment group, the intensive colonoscopy treatment group, and the autonomous monitoring group. During the three-year study period, the investigators observed changes in the number of adenomas, carcinogenesis, and medical expenses in each group during the 3-year study period, and compared the groups to determine whether the intensive colonoscopy therapy has the possibility of delaying or replacing preventive surgery.",[43],"2020-08-28",{"date":503,"type":91},"2020-08-31",{"date":505,"type":22},"2020-10-01",{"date":507,"type":22},"2030-09-30",{"name":509,"class":98},"Changhai Hospital"]